GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Gross-Profit-to-Asset %

Shire (SHPG) Gross-Profit-to-Asset % : 16.70% (As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Shire's annualized Gross Profit for the quarter that ended in Sep. 2018 was $10,856 Mil. Shire's average Total Assets over the quarter that ended in Sep. 2018 was $64,994 Mil. Therefore, Shire's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2018 was 16.70%.


Shire Gross-Profit-to-Asset % Historical Data

The historical data trend for Shire's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Gross-Profit-to-Asset % Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.52 45.94 36.03 18.12 15.52

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.02 17.05 15.53 16.77 16.70

Competitive Comparison of Shire's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Shire's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Shire's Gross-Profit-to-Asset % falls into.



Shire Gross-Profit-to-Asset % Calculation

Shire's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2017 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2017 )/( (Total Assets (A: Dec. 2016 )+Total Assets (A: Dec. 2017 ))/ count )
=10459.8/( (67035.4+67756.9)/ 2 )
=10459.8/67396.15
=15.52 %

Shire's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2018 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2018 )/( (Total Assets (Q: Jun. 2018 )+Total Assets (Q: Sep. 2018 ))/ count )
=10856.4/( (66222.1+63765.9)/ 2 )
=10856.4/64994
=16.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2018) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Shire Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Shire's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085

Shire (SHPG) Headlines

From GuruFocus

Publication of Scheme Document

By Marketwired Marketwired 11-12-2018